‘The hangover can last longer than the party’: Biotech is in a major slump, with no end in sight
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Signs of hiring at Boston-area life sciences companies
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
pharmaphorum1d
Biogen protects Tecfidera via $1.25bn deal with Forward
Massachusetts-based Biogen will pay Forward $1.25 billion upfront, and under a licence agreement may pay future royalties from Tecfidera dependent on ongoing patent cases in US and EU.
Yahoo Finance23d
Biogen buys rights to Stoke’s rare epilepsy drug
Per deal terms, the Massachusetts-based biotechnology company also granted Biogen an option to license rights to certain follow-on products that work in similar ways as zorevunersen. The drug is ...
Barchart on MSN17d
Biogen Stock Outlook: Is Wall Street Bullish or Bearish?
Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases.
PipelineReview.com1d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
The Business Journals23d
Major Mass. employers banish ‘diversity’ from annual filings
The four companies with a significant number of employees in Massachusetts — RTX, GE Aerospace, Biogen and CVS — are by no means the only ones that appear to have eliminated the word ...
Business Wire23d
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
American Association of Individual Investors20d
Which Is a Better Investment, Biogen Inc. or Insmed Incorporated Stock?
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...
Pharmabiz18h
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...